Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
S Kho, KJ Seung, H Huerga, M Bastard… - Nature …, 2024 - nature.com
Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment
failure. We analyze data from the endTB multi-country prospective observational cohort …
failure. We analyze data from the endTB multi-country prospective observational cohort …
Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis
L Trevisi, MA Hernán, CD Mitnick, U Khan… - American journal of …, 2023 - atsjournals.org
Rationale: Current recommendations for the treatment of rifampicin-and multidrug-resistant
tuberculosis include bedaquiline (BDQ) used for 6 months or longer. Evidence is needed to …
tuberculosis include bedaquiline (BDQ) used for 6 months or longer. Evidence is needed to …
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed
after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb …
after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb …
Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin-or Multidrug-Resistant Tuberculosis in Kazakhstan
M Rashitov, MF Franke, L Trevisi… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background In 2019, the World Health Organization called for operational research
on all-oral shortened regimens for multidrug-and rifampicin-resistant tuberculosis (MDR/RR …
on all-oral shortened regimens for multidrug-and rifampicin-resistant tuberculosis (MDR/RR …
Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in …
Background A low body mass index (BMI) at the start of treatment for rifampicin-or multidrug-
resistant tuberculosis (MDR/RR-TB) is associated with poor treatment outcomes and may …
resistant tuberculosis (MDR/RR-TB) is associated with poor treatment outcomes and may …
Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations: Applied and Methodological Analyses
L James - 2024 - dash.harvard.edu
In this dissertation, I employed three different analytic lenses to help improve health policy
decisions. Each chapter focuses on either tuberculosis (TB) or sickle cell disease (SCD) …
decisions. Each chapter focuses on either tuberculosis (TB) or sickle cell disease (SCD) …
[PDF][PDF] MAJOR ARTICLE
MD Makhmujan Rashitov, M Franke, L Trevisi… - 2024 - researchgate.net
Background: In 2019, WHO called for operational research on all-oral shortened regimens
for multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and …
for multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and …